Download
drugs in pregnancy n.
Skip this Video
Loading SlideShow in 5 Seconds..
Drugs in Pregnancy PowerPoint Presentation
Download Presentation
Drugs in Pregnancy

Drugs in Pregnancy

10 Views Download Presentation
Download Presentation

Drugs in Pregnancy

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Drugs in Pregnancy الدكتور محمد طباع كلية الطب / جامعة دمشق Mohammed Tabbaa, M.D., FACOG

  2. Placental barrier • Placenta allows the transfer of many drugs and dietary substances. • Lipid soluble compounds rapidly crosses the placenta, water soluble substances pass less. • The greater the molecular weight the less it passes through placenta. • The degree to which a substance is bound to plasma protein.

  3. Congenital malformations • The incidence of major malformation in general population is 2-3 % • Major Malformation : incompatible with survival such as Anencephaly or requiring major surgery for correction such as cleft palate or congenital hear disease, or producing major dysfunction in life (cerebral palsy). • Minor Malformation : if is included such as ear tag, extra finger … the rate is as high as 7-10%

  4. Thalidomide was not found to be teratogenic in rats and mice but a potent human teratogen. Corticosteroids cause cleft palate in mice while cause no harm in humans. Marked Species Specificity in Drug Teratogenicity

  5. Congenital malformations Genetic 25% Environmental Unknown 65% Drug exposure accounts for 2-3 % of all birth defects

  6. The Food & Drug Administration (FDA) list 5 categories of labeling drugs in pregnancy A Controlled studies in women fail to demonstrate a risk to the fetus in the first trimester. Animal studies do not indicate a risk t the fetus, there are no controlled human study. Studies have shown the drug to have animal teratogenic or embryocidal effects, but no controlled studies are available in women. B C

  7. The Food & Drug Administration (FDA) list 5 categories of labeling drugs in pregnancy Positive evidence of human fetal risk exists, but benefits in certain situations may make use of the drug acceptable inspite its risk. Studies in animals or humans have demonstrated fetal abnormalities or evidence demonstrated fetal risk based on human experience, or both, and the risk clearly outweigh any possible benefits D X

  8. Drugs should ONLY used when necessary. • The risk - benefit ratio should justify the use of certain drug. • The minimum effective dose should be employed. • As long term effects of drug exposure in utero may not be revealed for many years caution with regards to the use of any drug in pregnancy is warranted ( DES ).

  9. Until about day 3 after conception any cell is thought to be totipotential able to develop to any organ system. • Separation of the cells during this period can give the rise to monozygotic twins.

  10. The blastocyst is located in the uterus where implantation occurs 6-9 days after conception. • One group of cells forms the inner cell mass that will • develop into the fetus. • The inner cell mass will differentiate into three cell • layers

  11. Ectoderm Brain – Nerves – Skin Lining of digestive tract – Respiratory tract – Part of the bladder – Liver - Pancreas Connective tissue – cartilage – muscle- blood vessels – heart – kidneys - Gonads. Endoderm Mesoderm

  12. The group of cells forming the periphery of the blastocyst is termed the trophoblast. The placenta and fetal membranes will develop from this outer cell layer.

  13. From 3 – 8 weeks the embryonic disk undergoes major • development and will lay the foundation for all organ • systems and the blueprints for this human are set

  14. 5 weeks • After conception embryo assume features of human appearance. • Face is recognizable formation of eyes ears and nose. • Limbs emerges, digits cartilage and muscles develop. • Liver producing blood cells and bile. • Cerebral hemisphere begins to fill the brain area • The heart is beating at 5 weeks and completely developed by 8th week.

  15. Effects of Specific Drugs

  16. X Estrogen & Progesterone • Oral contraceptives and other hormones blamed in the past for a variety of birth defects but recent studies have NOT confirmed any teratogenic risk for these drugs. • Data from the Collaborative Perinatal Project (studied 50.000 pregnancies) found NO association between exposure and fetal congenital malformation.

  17. X Androgenic Steroids • Progestational agents-testosterone derivatives (Danazol) causes clitoromegaly and labial fusion if given before 13 weeks. • Can be corrected surgically

  18. Anticonvulsants D Valproic Acid (Depakene) • Carries 1-5 % risk of neuro tubal defect and other abnormalities • Spina bifida occurs in Depakene more than anencephaly with a ratio of 5:1 Fetal Valproate Syndrome

  19. D Phenytoin (Dilantin) • Decreases folate absorption and lowers the serum folate which has been implicated in birth defects so it is recommended to give folic acid supplement to women taking Dilantin (4 mg /day). • Fewer than 10% of offspring show the fetal hydantoin syndrome : Microcephaly - Growth deficiency – Developmental delay – Mental retardation – Dysmorphic craniofacial features-Cleft lip\palate – Hypoplasia of nails and distal phalanges.

  20. C Trimethadione (Tridione) & Carbamazepine (Tegretol) • Also associated with dysmorphic syndrome, but children exposed to Dilantin scored 10 points less in the IQ score than those exposed to Tegretol. • It is recommended to adjust the dose of medications and obtain monthly blood levels to give the least possible dose.

  21. X Isotretinoin (Accutane) • Used mainly in the treatment of cystic acne. • 154 exposed human pregnancies reported to date 21 reported birth defects, 12 spontaneous abortions, 95 elective abortions and 26 normal infants. • Structural defects and mental retardation • Microtia \ anotia (small \ absent ears) micrognathia, cleft palate, heart defects (great vessels transposition and VSD), thymic defects, CNS malformations including hydrocephalus and optic nerve and retinal anomalies. • It is not detected after 5 days from ingestion in serum. • Topical tretinoin has not been associated with any teratogenic risk.

  22. A Vitamin A • There is NO evidence that vitamin A itself in normal doses is teratogenic. • The levels in prenatal vitamins are 5.000 IU\day orally. • 18 cases of birth defects reported after exposure to levels of 25.000 IU\day. • Vitamin A in doses greater than 10.000 IU\day increases the risk of malformations.

  23. D Lithium • In the International Register of Lithium Babies 217 are exposed at least during the first trimester of pregnancy 25 (11.5 %) were malformed, 18 had cardiovascular anomalies including six cases of the rare Ebstein anomaly .(anomaly of tricuspid valve) • of the 60 unaffected infants were followed to age 5 years were normal. • 2 cases of polyhydramnios reported because of nephrogenic diabetes insipidus in adults taking Lithium the presumed mechanism of polyhydramnios if fetal diabetes insipidus and polyhydramnios may indicate fetal Lithium toxicity. • It is recommended to change medication during pregnancy although replaces are as high as 70% in one year as opposed to 20% to those who remain on Lithium

  24. Antidepressants Imipramine (Tofranil) D • The original tricyclic antidepressant claimed to be associated with cardiovascular defects but the number of cases studied are small (75 newborn 6 had CVS anomalies) • Widely used 2 major studies showed NO increased risk of major malformations in so far 237 infants exposed in utero. B Fluoxetine (Prozac)

  25. D Warfarin (Coumadin) • The drug has been associated with Warfarin embryopathy seen in 5% of exposed pregnanciesincludes : Nasal hypoplasia – Bone stippling – ophthalmalgics anomalies including bilateral optic atrophy and mental retardation (seen even when exposed later than 1st ). • Heparin is an alternative drug does NOT cross the placenta because of high molecular weight.

  26. D Thyroid & Antithyroid Drugs • Propylthiouracil (PTU) and Methimazole (Tapazole) both cross the placenta and may cause a degree of fetal goiter while the thyroid hormones T3 & T4 cross the placenta poorly so that fetal hypothyroid can not be corrected by giving the mother thyroid hormone. • It is suggested to keep the mother slightly hyperthyroid. • Methimazole (Tapazole) has been associated with scalp defects in infants, so Propylthiouracil (PTU) is the drug of choice

  27. Radioactive Iodine • Radio active Iodine for thyroid ablation 131I &125I or for diagnostic studies is not concentrated by the fetal thyroid till 12 weeks. • Early inadvertent exposure carries NO specific risk. • Topical Iodine preparation are absorbed through vagina.

  28. C Digoxin • In 52 exposures reported NO teratogenicity of digoxin was noted • It is used in fetal therapy. • Maternal blood levels should be monitored during pregnancy. • In hydropic fetuses digoxin may not easily cross the placenta.

  29. Antihypertensive Drugs • Alpha Methyl Dopa (Aldomet) has been widely used for the treatment of chronic hypertension in pregnancy. • Hydralazine (Apresoline) has also been widely used in pregnancy. No Unusual Fetal Effects B

  30. Sympathetic Blocking Agents C • Propranolol (Inderal)b - adrenergic blocking agent, theoretically might increase uterine contractility but this has not been reported. As the drug is not specific for b2 receptors in the uterus. • NO evidence of teratogenicity. • Fetal bradycardia is seen. • New studies associated Inderal with increased risk of IUGR.

  31. D Angiotensin-Converting Enzyme Inhibitors (ACE) • Enalapril (Vasotec), Captopril (Capoten) can cause fetal renal failure in the 2nd and 3rd leading to oligohydramnios, fetal limb contractures, craniofacial deformities and hypoplastic lung development. • Its use during the 1st has NOT been reported to be teratogenic.

  32. Antineoplastic Drugs & Immunosuppressants D Methotrexate • Folic acid antagonist appears to be human teratogen although experience with it is limited. • Used in patients with renal transplants or SLE of 80 women treated in the 1st anomalies was NOT increased. 2 infants has leukopenia, one has IUGR D Azathioprine (Imuran)

  33. C Cyclosporine • 67 infants exposed in utero NO increased risk of anomalies. • Increased risk of prematurity and IUGR. • NO risk of anomalies when given in prophylactic doses for Malaria among 169 infants exposed to 300 mg weekly. • Doses of 250-500 mg daily TWO cases reported of cochleovestibular paresis. C Chloroquine

  34. Antiasthmatics C Theophylline & Aminophylline • Both are SAFE for the treatment of asthma in pregnancy. NO evidence of teratogenic risk in 76 exposures in the Collaborative Perinatal Project. • Minor malformations have been reported with sympathomimetic as a group in 3082 exposures in the 1st • Used in preterm labor NO Risk of birth defects has been reported C Epinephrine B Terbutaline

  35. Corticosteroids B • All steroids cross the placenta to some degree but Prednisone and Prednisolone are inactivated by the placenta. • Only 10% of the maternal dose reaches the fetus, the drug of choice in treating asthma in pregnancy. • Betamethasone & Dexamethasone they are minimally inactivated by placenta. Used for fetal lung maturity. • Several hundred infants exposed to corticosteroids in the 1st NO abnormalities was noted. • Saturated solution of potassium Iodide (SSKI) expectorant crosses the placenta causes large fetal goiter to produce respiratory obstruction. C D Iodide

  36. Vitamin B6 A • Vitamin B6 (Pyridoxine) reported in 2 randomized placebo controlled studies to be effective for treating nausea and vomiting in pregnancy. • In several other controlled trial NO evidence of teratogenicity. • In 595 patients treated in the Collaborative Perinatal Project NO teratogenicity was noted. (Drowsiness can be a problem) Diphenhydramine (Benadryl) C

  37. Phenothiazine Chlorpromazine (Thorazine) C • Very effective in the treatment of hyperemesis gravidarum. • 976 patients treated in the Kaiser Health Plan. • 1309 patients treated in the Collaborative Perinatal Project NO Fetal Malformations Noted • 58 mothers treated NO risk of malformation C Promethazine (Phenergan)

  38. Antihistamines • NO increased risk of anomalies has been associated with most antihistaminics used. • An association between exposure during the last 2 weeks of pregnancy to antihistaminics in general and retrolental fibroplasia in premature infants has been reported. • One retrospective study showed increased risk of gastroschisis was associated with 1st pseudoephedrine (Sudafed) use.

  39. Antibiotics Penicillins B • Penicillin, ampicillin and amoxicillin are safe in pregnancy • 3546 patients in the Collaborative Perinatal Project mothers took penicillin in the 1st with NO increased risk of anomalies • Transplacental passage of penicillin is by simple diffusion, high protein binding penicillins e.g. oxacillin, cloxacillin and dicloxacillin cross the placenta less than poorly bound penicillin e.g. penicillin and ampicillin

  40. Cephalosporins B • In a study of 5000 Michigan Medicaid Recipients there was a suggestion of possible teratogenicity with Cefaclor, Cephalexin and Cephradine • 1455 human infants exposed to sulfonamides in the 1st NO teratogenic effects. • These drugs should be avoided in women deficient in G6PD. • There is a theoretical risk of hemolysis in the fetus if drug is used near delivery as fetal red cells are deficient in glutathione. Sulfonamides B

  41. Sulfamethoxazole (Bactrim) C • Two published trials have failed to show any increased risk of birth defects. • One Unpublished study of 2000 Michigan Medicaid Recipients suggested increased risk of cardiovascular defects after exposure in the 1st • 590 infants were exposed in the Collaborative Perinatal Project 80 in the 1st NO increased risk of abnormality, more recent studies confirmed these findings. • Macrodantin can cause anemia in patients deficient in G6PD and theoretically in infants. Nitrofurantoin (Macrodantin) B

  42. Tetracycline D • Readily crosses the placenta and firmly bound by chelation to calcium in the developing bone and tooth structures. • This leads to brown discoloration hypoplasia of the enamel and inhibition of bone growth. The staining of the teeth takes place in the 2nd & 3rd • Hepatotoxicity has been reported in pregnant women using large doses of tetracycline. • 341 exposed infants in the 1st in the collaborative perinatal Project and another 174 women in other study found NO teratogenic effects.

  43. B Erythromycin • 9 patients in Collaborative Perinatal project and 260 patients in another study NO teratogenic risk or increased birth defects. • Erythromycin estolate (Ilosone) has been associated with subclinical reversible hepatotoxicity during pregnancy. • Several studies showed NO risk of congenital defects with the use of Flagyl early and late in pregnancy. • Some controversy rose when Metronidazole showed to be mutagenic in bacteria by the Ames test, which correlates with carcinogenicity in animals. Its carcinogenicity in human has not been confirmed Metronidazole B

  44. Quinolones (Cipro) C • The quinolones have a high affinity for bone tissue and cartilage and may cause bone stippling and arthralgia if given in utero or to young children. • 38 infants exposed to quinolones in utero in the 1st NO abnormalities noted. • The Acyclovir Register has recorded 601 exposure during pregnancy including 425 in the 1st with NO increased risk of abnormalities. • The CDC recommended its use in pregnant women with disseminated infection (herpes encephalitis or hepatitis) C Acyclovir (Zovirax)

  45. Antifungal B • Nystatin (Mycostatin) poorly absorbed from intact skin and mucus membranes, topical use has NOT been associated with teratogenesis. • The Imidazoles are absorbed in small amounts from vagina has NOT been associated with congenital malformation • One study showed a statistically significantly increased risk of 1st abortion.

  46. Aspirin C • NO evidence of any teratogenic effect of aspirin taken in the 1st • Aspirin inhibits prostaglandin synthesis leads to decrease uterine contractions and delay onset of labor. • Aspirin also decrease platelets aggregation increase risk of bleeding. As well as in infants up to 5 days after exposure. • NO evidence of teratogenicity. • It inhibits prostaglandin synthesis but in reversible manner. Acetaminophen (Tylenol-Panadol) B

  47. NSAD B • NO evidence of teratogenicity has been reported for nonsteroidal anti-inflammatory drugs. • Chronic use may lead to oligohydramnios and constriction of fetal ductus arteriosus or pulmonary hypertension has been reported with Indomethacin use. • In the Collaborative perinatal Project NO increased risk of malformations • Codeine can be addictive and may lead to infant withdrawal symptoms. Codeine C